NCT05263583: An overdue trial by Cothera Bioscience, Inc
This trial is overdue. It was due to report 2 months, 3 weeks ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT05263583 |
|---|---|
| Title | A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 9, 2022 |
| Completion date | March 1, 2025 |
| Required reporting date | March 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | 82 |